Broadview Advisors LLC decreased its holdings in Natera Inc (NASDAQ:NTRA) by 21.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 434,002 shares of the medical research company’s stock after selling 115,175 shares during the quarter. Broadview Advisors LLC’s holdings in Natera were worth $8,168,000 as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in the business. Northern Trust Corp raised its position in Natera by 1.5% in the first quarter. Northern Trust Corp now owns 375,674 shares of the medical research company’s stock worth $3,483,000 after acquiring an additional 5,428 shares in the last quarter. Swiss National Bank raised its position in Natera by 13.2% in the first quarter. Swiss National Bank now owns 47,900 shares of the medical research company’s stock worth $444,000 after acquiring an additional 5,600 shares in the last quarter. Trexquant Investment LP purchased a new position in Natera in the first quarter worth $119,000. Geode Capital Management LLC raised its position in Natera by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 352,850 shares of the medical research company’s stock worth $3,172,000 after acquiring an additional 13,708 shares in the last quarter. Finally, MetLife Investment Advisors LLC purchased a new position in Natera in the fourth quarter worth $124,000. Hedge funds and other institutional investors own 73.00% of the company’s stock.
Shares of Natera traded down $0.37, reaching $22.50, during mid-day trading on Monday, MarketBeat reports. The stock had a trading volume of 14,890 shares, compared to its average volume of 788,926. Natera Inc has a 12-month low of $7.78 and a 12-month high of $24.07. The stock has a market cap of $1.25 billion, a P/E ratio of -9.38 and a beta of 1.98. The company has a quick ratio of 1.68, a current ratio of 1.80 and a debt-to-equity ratio of -18.90.
Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, May 8th. The medical research company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The company had revenue of $62.34 million for the quarter, compared to analyst estimates of $54.86 million. Natera had a negative net margin of 58.84% and a negative return on equity of 752.93%. The firm’s revenue was up 26.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.70) EPS. sell-side analysts anticipate that Natera Inc will post -2.02 earnings per share for the current year.
A number of research analysts have recently weighed in on the company. ValuEngine upgraded Natera from a “hold” rating to a “buy” rating in a research report on Wednesday, June 6th. BidaskClub upgraded Natera from a “hold” rating to a “buy” rating in a research report on Saturday, June 16th. Craig Hallum assumed coverage on Natera in a research report on Monday, April 9th. They issued a “buy” rating and a $16.00 price target for the company. Canaccord Genuity raised their price target on Natera from $19.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, June 25th. Finally, Zacks Investment Research upgraded Natera from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research report on Tuesday, July 17th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Natera presently has an average rating of “Buy” and a consensus price target of $20.00.
In related news, CFO Michael Burkes Brophy sold 26,870 shares of the stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $18.29, for a total transaction of $491,452.30. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Steven Leonard Chapman sold 86,919 shares of the stock in a transaction on Monday, June 25th. The shares were sold at an average price of $18.00, for a total value of $1,564,542.00. Following the sale, the chief operating officer now directly owns 3,588 shares in the company, valued at approximately $64,584. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 178,364 shares of company stock worth $2,801,816. Corporate insiders own 13.18% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: Should I invest in “strong buy” stocks?
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.